Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric phase 2/3 trial of imipenem/cilastatin/relebactam for serious gram-negative infections
MOH_2019-08-21_006000Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imipenem + cilastatin + relebactam in complicated urinary tract infection (cUTI), Intra-abdominal infection (IAI), hospital-acquired pneumonia (HAP) and 2 more (2 arms), sponsored by Merck & Co. Primary endpoints: Safety, Pharmacokinetics and 1 more. Started Jun 2019; status: completed.
02
Drugs
imipenem + cilastatin + relebactam
03
Conditions
complicated urinary tract infection (cUTI)Intra-abdominal infection (IAI)hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Gram-negative bacterial infection
Beyond the preview
Go deeper on MOH_2019-08-21_006000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-08-21_006000.